CEFOPERAZONE SODIUM (sef-oh-per'a-zone) Cefobid Classifications: antiinfective; antibiotic; third-generation cephalosporin Prototype: Cefotaxime sodium Pregnancy Category: B |
1 g, 2 g injection
Semisynthetic third-generation cephalosporin antibiotic. Preferentially binds to one or more of the penicillin-binding proteins (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis, thus killing the bacterium. Spectrum of activity is similar to that of cefotaxime.
Generally active against a wide variety of gram-negative bacteria, including some strains of Pseudomonas aeruginosa. Also active against some organisms resistant to first and second generation cephalosporins and currently available aminoglycoside antibiotics and penicillins: e.g., Escherichia coli, Klebsiella pneumoniae, and Serratia marcescens. Other susceptible organisms include Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae, Neisseria gonorrhoeae, groups A and B Streptococci, Staphylococcus aureus, and some strains of Pseudomonas sp. Cefoperazone inhibits some strains of Clostridium, but C. difficle is resistant to the drug, as is Listeria monocytogenes. It has a broad antibacterial spectrum, including gram-positive bacteria and Pseudomonas aeruginosa. Effectively treats biliary tract infections, gynecologic infections and gonorrhea, intra-abdominal and soft tissue infections, respiratory tract infections, urinary tract infections, skin infections, septicemia, and surgical infections, reducing or eliminating signs and symptoms of infection.
Infections of skin and skin structures, urinary tract, respiratory tract; peritonitis and other intra-abdominal infections, pelvic inflammatory disease, endometritis and other infections of the female genital tract; bacterial septicemia.
Children <12 y.
Hypersensitivity to cephalosporins and related beta-lactam antibiotics; pregnancy (category B).
History of hypersensitivity to penicillins, history of allergy, particularly to drugs; hepatic disease, history of colitis or other GI disease, history of bleeding disorders; lactation.
Moderate to Severe Infections Adult: IV/IM 12 g q12h; 16 g/d in 24 divided doses Child <12 y : IV/IM 100150 mg/kg/d divided q812h (max: 12 g/d) |
Intravenous
PREPARE: Intermittent: Dilute each 1 g with 5 mL sterile water. Shake vigorously to dissolve, then dilute in 50100 mL of D5W or NS. Continuous: Further dilute in 5001000 mL of the selected IV solution. ADMINISTER: Intermittent: Give over 1530 min. Continuous: Give 5001000 mL over 624 h. INCOMPATIBILITIES Solution/additive: aminoglycosides, doxapram. Y-site: aminoglycosides, amifostine, amphotericin B cholesteryl complex, cisatracurium, diltiazem, doxorubicin liposome, filgrastim, gemcitabine, hetastarch, labetalol, meperidine, ondansetron, pentamidine, perphenazine, promethazine, sargramostim, vinorelbine. |
Cefoperazone can cause positive direct Coombs' test, which may result in interferences with hematologic studies and cross-matching procedures. False-positive results for urine glucose using copper sulfate tests (Benedict's, Clinitest), but not with glucose enzymatic tests, e.g., Clinistix, TesTape, Diastix. Also causes prolonged prothrombin twice during therapy.
Assessment & Drug Effects
Patient & Family Education